SlideShare ist ein Scribd-Unternehmen logo
1 von 1
Trabeculectomy with Mitomycin for Open-Angle Glaucoma in Phakic
versus Pseudophakic Eyes After Clear-Corneal Phacoemulsification
H. George Tanaka, M.D. and Edie De Niro, M.D., California Pacific Medical Center, San Francisco CA
Research Question
Methods
•Retrospective Cohort Study
•Patients with open-angle glaucoma
who underwent trabeculectomy
between 1992 and 2012
•Study Group: 63 eyes (57 patients)
with history of uncomplicated
temporal clear corneal
phacoemulsification before
trabeculectomy
•Control Group: 108 eyes (81 patients)
with no history of eye surgery before
trabeculectomy
•Inclusion criteria: Pre-trabeculectomy
IOP ≥ 18 mmHg and ≤ 40 mmHg. No
uveitis or neovascular glaucoma.
•Trabeculectomy was fornix-based,
suture-lysis was used, and mitomycin
C dose varied with surgeon
Outcome Measure
Trabeculectomy Failure, defined as:
1. IOP ≥ 21 mm Hg or not reduced
by 20% below baseline on 2
consecutive follow-up visits
after 3 months
2. IOP ≤ 5 mm Hg on 2
consecutive follow-up visits
after 3 months
3. Reoperation for glaucoma
4. Loss of light-perception vision
Results
31.7%
Results
Does clear-corneal phacoemulsification
affect subsequent trabeculectomy?
P =
0.107
Kaplan Meier Analysis
Months of Follow-up
(mean 13.4 months)
Green = Pseudophakic Eyes
Blue = Control Eyes
Conclusions
Clear corneal phacoemulsification
does not appear to adversely impact
subsequent trabeculectomy. Study
limitations include relatively small
sample size, retrospective
methodology and limited follow-up
time.
0
10
20
30
40
50
Pseudophakic
Eyes
Control Eyes (no
previous
surgery)
Percentage failing
n = 63 n = 108
42.6%

Weitere ähnliche Inhalte

Was ist angesagt?

DME -DIABETIC MACULAR EDEMA - cases-DR AJAY DUDANI
DME -DIABETIC MACULAR EDEMA - cases-DR AJAY DUDANIDME -DIABETIC MACULAR EDEMA - cases-DR AJAY DUDANI
DME -DIABETIC MACULAR EDEMA - cases-DR AJAY DUDANI
AjayDudani1
 
Humphrey gpa overview training edition.v.2
Humphrey gpa overview   training edition.v.2Humphrey gpa overview   training edition.v.2
Humphrey gpa overview training edition.v.2
Hossein Mirzaie
 
dr Oh's article in Korean CLsociety journal
dr Oh's article in Korean CLsociety journaldr Oh's article in Korean CLsociety journal
dr Oh's article in Korean CLsociety journal
somi oh
 
Eyelid malignancies in Bangladesh.ppt
Eyelid malignancies in Bangladesh.pptEyelid malignancies in Bangladesh.ppt
Eyelid malignancies in Bangladesh.ppt
Syeed Kadir
 

Was ist angesagt? (20)

IPCV MGT WITH PDT
IPCV MGT WITH PDTIPCV MGT WITH PDT
IPCV MGT WITH PDT
 
Comparative study of the results of 0.04%da mitomycin c and simple conjunctiv...
Comparative study of the results of 0.04%da mitomycin c and simple conjunctiv...Comparative study of the results of 0.04%da mitomycin c and simple conjunctiv...
Comparative study of the results of 0.04%da mitomycin c and simple conjunctiv...
 
Anterior Segment Company Showcase - Avedro
Anterior Segment Company Showcase - AvedroAnterior Segment Company Showcase - Avedro
Anterior Segment Company Showcase - Avedro
 
DME -DIABETIC MACULAR EDEMA - cases-DR AJAY DUDANI
DME -DIABETIC MACULAR EDEMA - cases-DR AJAY DUDANIDME -DIABETIC MACULAR EDEMA - cases-DR AJAY DUDANI
DME -DIABETIC MACULAR EDEMA - cases-DR AJAY DUDANI
 
Nw2014 Diabetic Macular Edema Treatment Options
Nw2014 Diabetic Macular Edema Treatment OptionsNw2014 Diabetic Macular Edema Treatment Options
Nw2014 Diabetic Macular Edema Treatment Options
 
celiac
celiacceliac
celiac
 
Ophthalmology Innovation Showcase 1 - InnFocus (A Santen Company)
Ophthalmology Innovation Showcase 1 - InnFocus (A Santen Company)Ophthalmology Innovation Showcase 1 - InnFocus (A Santen Company)
Ophthalmology Innovation Showcase 1 - InnFocus (A Santen Company)
 
Protocol s
Protocol sProtocol s
Protocol s
 
Treatment Options in CI DME at APACRS 2016: A Presentation by Dr Somdutt Prasad
Treatment Options in CI DME at APACRS 2016: A Presentation by Dr Somdutt PrasadTreatment Options in CI DME at APACRS 2016: A Presentation by Dr Somdutt Prasad
Treatment Options in CI DME at APACRS 2016: A Presentation by Dr Somdutt Prasad
 
Ophthalmology Innovation Showcase 2 - Avedro
Ophthalmology Innovation Showcase 2 - AvedroOphthalmology Innovation Showcase 2 - Avedro
Ophthalmology Innovation Showcase 2 - Avedro
 
Humphrey gpa overview training edition.v.2
Humphrey gpa overview   training edition.v.2Humphrey gpa overview   training edition.v.2
Humphrey gpa overview training edition.v.2
 
Erectile Dysfunction and Penile Implant: the best solution for the worst situ...
Erectile Dysfunction and Penile Implant: the best solution for the worst situ...Erectile Dysfunction and Penile Implant: the best solution for the worst situ...
Erectile Dysfunction and Penile Implant: the best solution for the worst situ...
 
Ophthalmology Innovation Showcase 2 - Presbyopia Therapies
Ophthalmology Innovation Showcase 2 - Presbyopia TherapiesOphthalmology Innovation Showcase 2 - Presbyopia Therapies
Ophthalmology Innovation Showcase 2 - Presbyopia Therapies
 
dr Oh's article in Korean CLsociety journal
dr Oh's article in Korean CLsociety journaldr Oh's article in Korean CLsociety journal
dr Oh's article in Korean CLsociety journal
 
Orthokeratology and Its Effects on Children
Orthokeratology and Its Effects on ChildrenOrthokeratology and Its Effects on Children
Orthokeratology and Its Effects on Children
 
Profile of secondary glaucoma cases in a tertiary eye care centre.
Profile of secondary glaucoma cases in a tertiary eye care centre.Profile of secondary glaucoma cases in a tertiary eye care centre.
Profile of secondary glaucoma cases in a tertiary eye care centre.
 
Git j club esge optical diagnosis21
Git j club esge optical diagnosis21Git j club esge optical diagnosis21
Git j club esge optical diagnosis21
 
Eyelid malignancies in Bangladesh.ppt
Eyelid malignancies in Bangladesh.pptEyelid malignancies in Bangladesh.ppt
Eyelid malignancies in Bangladesh.ppt
 
What is videonystagmography
What is videonystagmographyWhat is videonystagmography
What is videonystagmography
 
Posterior Segment Company Showcase - Alimera Sciences
Posterior Segment Company Showcase - Alimera SciencesPosterior Segment Company Showcase - Alimera Sciences
Posterior Segment Company Showcase - Alimera Sciences
 

Andere mochten auch

Andere mochten auch (14)

Just Be Nice: Rethinking Tech Hiring
Just Be Nice: Rethinking Tech HiringJust Be Nice: Rethinking Tech Hiring
Just Be Nice: Rethinking Tech Hiring
 
行政院簡報 衛福部(媒體版簡報)
行政院簡報 衛福部(媒體版簡報)行政院簡報 衛福部(媒體版簡報)
行政院簡報 衛福部(媒體版簡報)
 
Finalppt_group11
Finalppt_group11Finalppt_group11
Finalppt_group11
 
Finalppt_group17
Finalppt_group17Finalppt_group17
Finalppt_group17
 
Rubéola
RubéolaRubéola
Rubéola
 
How Constraints Cultivate Growth
How Constraints Cultivate GrowthHow Constraints Cultivate Growth
How Constraints Cultivate Growth
 
2016 iirsi brochure
2016 iirsi brochure2016 iirsi brochure
2016 iirsi brochure
 
Fotografos de moda
Fotografos de modaFotografos de moda
Fotografos de moda
 
αρετη αγαπη-4
αρετη αγαπη-4αρετη αγαπη-4
αρετη αγαπη-4
 
How To Get Your Next Job as a Developer
How To Get Your Next Job as a DeveloperHow To Get Your Next Job as a Developer
How To Get Your Next Job as a Developer
 
Understanding Open Source Licenses
Understanding Open Source LicensesUnderstanding Open Source Licenses
Understanding Open Source Licenses
 
Señales de transito
Señales de transitoSeñales de transito
Señales de transito
 
行政院簡報 衛福部(懶人包)
行政院簡報 衛福部(懶人包)行政院簡報 衛福部(懶人包)
行政院簡報 衛福部(懶人包)
 
Climantica 2016 diego freeman
Climantica 2016 diego freemanClimantica 2016 diego freeman
Climantica 2016 diego freeman
 

Ähnlich wie AGS 2014

Ähnlich wie AGS 2014 (20)

EAGLE study
EAGLE studyEAGLE study
EAGLE study
 
Angle Recession Glaucoma
Angle Recession GlaucomaAngle Recession Glaucoma
Angle Recession Glaucoma
 
Iridodialysis repair with modified double armed closed chamber technique
Iridodialysis repair with modified double armed closed chamber techniqueIridodialysis repair with modified double armed closed chamber technique
Iridodialysis repair with modified double armed closed chamber technique
 
MIGS
MIGSMIGS
MIGS
 
Central Retinal Vein OcclUsIon (CRUISE) Study - Cruise trial
Central Retinal  Vein OcclUsIon (CRUISE) Study - Cruise trialCentral Retinal  Vein OcclUsIon (CRUISE) Study - Cruise trial
Central Retinal Vein OcclUsIon (CRUISE) Study - Cruise trial
 
iStent infinte.pptx
iStent infinte.pptxiStent infinte.pptx
iStent infinte.pptx
 
Phaco - PhacoTrabec.pptx
Phaco - PhacoTrabec.pptxPhaco - PhacoTrabec.pptx
Phaco - PhacoTrabec.pptx
 
Glaucoma Filtration Surgery Study
Glaucoma Filtration Surgery StudyGlaucoma Filtration Surgery Study
Glaucoma Filtration Surgery Study
 
Diabetic retinopathy guidlines
Diabetic retinopathy guidlinesDiabetic retinopathy guidlines
Diabetic retinopathy guidlines
 
InnFocus
InnFocus InnFocus
InnFocus
 
09 long term-follow-up
09 long term-follow-up09 long term-follow-up
09 long term-follow-up
 
Congenital Glaucoma
Congenital  GlaucomaCongenital  Glaucoma
Congenital Glaucoma
 
Suprachoroidal Buckling BY DR.PUSHKAR DHIR.pptx
Suprachoroidal Buckling BY DR.PUSHKAR DHIR.pptxSuprachoroidal Buckling BY DR.PUSHKAR DHIR.pptx
Suprachoroidal Buckling BY DR.PUSHKAR DHIR.pptx
 
Myectomy non-suture technique for large angle strabismus surgery
Myectomy non-suture technique for large angle strabismus surgeryMyectomy non-suture technique for large angle strabismus surgery
Myectomy non-suture technique for large angle strabismus surgery
 
13 reoperation
13 reoperation13 reoperation
13 reoperation
 
Topical dorzolamide for macular edema in the early phase after vitrectomy and...
Topical dorzolamide for macular edema in the early phase after vitrectomy and...Topical dorzolamide for macular edema in the early phase after vitrectomy and...
Topical dorzolamide for macular edema in the early phase after vitrectomy and...
 
power point presentation of Macular Hole.pptx
power point presentation of Macular Hole.pptxpower point presentation of Macular Hole.pptx
power point presentation of Macular Hole.pptx
 
COVID-19 Pandemic And Lockdown: Indirect Impact On Chronic Eye Diseases
COVID-19 Pandemic And Lockdown: Indirect Impact On Chronic Eye DiseasesCOVID-19 Pandemic And Lockdown: Indirect Impact On Chronic Eye Diseases
COVID-19 Pandemic And Lockdown: Indirect Impact On Chronic Eye Diseases
 
Eyecare Myths
Eyecare MythsEyecare Myths
Eyecare Myths
 
Principles and technique of pneumatic retinopexy (Dr. Avuru C.J).pptx
Principles and technique of pneumatic retinopexy (Dr. Avuru C.J).pptxPrinciples and technique of pneumatic retinopexy (Dr. Avuru C.J).pptx
Principles and technique of pneumatic retinopexy (Dr. Avuru C.J).pptx
 

AGS 2014

  • 1. Trabeculectomy with Mitomycin for Open-Angle Glaucoma in Phakic versus Pseudophakic Eyes After Clear-Corneal Phacoemulsification H. George Tanaka, M.D. and Edie De Niro, M.D., California Pacific Medical Center, San Francisco CA Research Question Methods •Retrospective Cohort Study •Patients with open-angle glaucoma who underwent trabeculectomy between 1992 and 2012 •Study Group: 63 eyes (57 patients) with history of uncomplicated temporal clear corneal phacoemulsification before trabeculectomy •Control Group: 108 eyes (81 patients) with no history of eye surgery before trabeculectomy •Inclusion criteria: Pre-trabeculectomy IOP ≥ 18 mmHg and ≤ 40 mmHg. No uveitis or neovascular glaucoma. •Trabeculectomy was fornix-based, suture-lysis was used, and mitomycin C dose varied with surgeon Outcome Measure Trabeculectomy Failure, defined as: 1. IOP ≥ 21 mm Hg or not reduced by 20% below baseline on 2 consecutive follow-up visits after 3 months 2. IOP ≤ 5 mm Hg on 2 consecutive follow-up visits after 3 months 3. Reoperation for glaucoma 4. Loss of light-perception vision Results 31.7% Results Does clear-corneal phacoemulsification affect subsequent trabeculectomy? P = 0.107 Kaplan Meier Analysis Months of Follow-up (mean 13.4 months) Green = Pseudophakic Eyes Blue = Control Eyes Conclusions Clear corneal phacoemulsification does not appear to adversely impact subsequent trabeculectomy. Study limitations include relatively small sample size, retrospective methodology and limited follow-up time. 0 10 20 30 40 50 Pseudophakic Eyes Control Eyes (no previous surgery) Percentage failing n = 63 n = 108 42.6%